Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation
NCT02711826Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2016
- Primary completion
- Aug 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Polyclonal Regulatory T Cells in subclinical inflammation (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of Banff 2A or Higher Acute Cell-mediated Rejection and/or Acute Antibody Mediated Rejection at 405 days, Timing of Banff 2A or Higher Acute Cell-mediated Rejection and/or Acute Antibody Mediated Rejection at 405 days and 4 more. Started Sep 2016; status: completed.
02
Drugs
Polyclonal Regulatory T Cells
03
Conditions
subclinical inflammation
Beyond the preview
Go deeper on NCT02711826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711826.